Allopregnanolone and mood disorders

Progress in Neurobiology

Volumn 113, Issue , 2014, Pages 88-94

  Backstrom T ^a   Bixo, M ^a   Johansson, M ^a   Nyberg, S ^a   Ossewaarde, L ^b   Ragagnin, G ^a   Savic, I ^c   Stromberg J ^a   Timby, E ^a   van Broekhoven, F ^a   van Wingen, G ^d  

^a UMEÅ UNIVERSITY   (Sweden)

^b Department of Medical Psychology   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Allopregnanolone; Menstrual cycle; Paradoxical effects; Premenstrual dysphoric disorder

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4; BENZODIAZEPINE; DIAZEPAM; ELTANOLONE; FLUMAZENIL; MIFEPRISTONE; PROGESTERONE;

AMYGDALOID NUCLEUS; ANOVULATION; ANXIETY; BURNOUT; CHRONIC STRESS; CORPUS LUTEUM; DISEASE SEVERITY; ESTROGEN THERAPY; FOLLICULAR PHASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; HORMONE SUBSTITUTION; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; MENSTRUATION; MENTAL STRESS; MOOD CHANGE; MOOD DISORDER; NEGATIVE SYNDROME; NERVE POTENTIAL; NONHUMAN; ORBITAL CORTEX; PARADOXICAL DRUG REACTION; POSTMENOPAUSE; PREFRONTAL CORTEX; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN QUATERNARY STRUCTURE; REVIEW; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE;

ALLOPREGNANOLONE; CENTRAL NERVOUS SYSTEM; CNS; FMRI; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABA-A; GABA-A RECEPTOR MODULATING STEROIDS; GABA-AR; GAMMA-BUTYRIC-ACID-A; GAMMA-BUTYRIC-ACID-A RECEPTOR; GAMS; HORMONE REPLACEMENT THERAPY; HRT; MEDIAL PREFRONTAL; MEDROXYPROGESTERONE-ACETATE; MENSTRUAL CYCLE; MPA; MPFC; OFC; ORBITOFRONTAL CORTEX; PARADOXICAL EFFECTS; PMDD; PMS; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; SACCADIC EYE VELOCITY; SEV;

ANIMALS; BRAIN; FEMALE; HUMANS; MOOD DISORDERS; PREGNANOLONE; RECEPTORS, GABA-A;

EID: 84892847479     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2013.07.005     Document Type: Review

References (88)

1. Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav. Brain Res. 1999, 106:119-125.
2. Andréen L., Bixo M., Nyberg S., Sundström-Poromaa I., Bäckström T. Progesterone effects during sequential hormone replacement therapy. Eur. J. Endocrinol. 2003, 148:571-577.
3. Andréen L., Spigset O., Andersson A., Nyberg S., Bäckström T. Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low dose progesterone. Maturitas 2006, 54:238-244.
4. Andréen L., Sundström-Poromaa I., Bixo M., Andersson A., Nyberg S., Bäckström T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 2005, 30:212-224.
5. Andréen L., Sundström-Poromaa I., Bixo M., Nyberg S., Bäckström T. Allopregnanolone concentration and mood-a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl) 2006, 187:209-221.
6. Baloh R.W., Sills A.W., Kumley W.E., Honrubia V. Quantitative measurement of saccade amplitude, duration, and velocity. Neurology 1975, 25:1065-1070.
7. Beauchamp M.H., Ormerod B.K., Jhamandas K., Boegman R.J., Beninger R.J. Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol. Biochem. Behav. 2000, 67:29-35.
8. Becker W. Metrics. The Neurobiology of Saccadic Eye Movements 1989, 13-67. Elsevier science publishers BV, Amsterdam. R.H. Wurtz, M.E. Goldberg (Eds.).
9. Bell E.C., Baker G.B., Poag C., Bellavance F., Khudabux J., Le Melledo J.M. Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females. Psychopharmacology (Berl) 2004, 172:248-254.
10. Ben-Porath D.D., Taylor S.P. The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation. Addict. Behav. 2002, 27:167-177.
11. Biciková M., Lapcik O., Hampl R., Starka L., Knuppen R., Haupt O., Dibbelt L. A novel radioimmunoassay of allopregnanolone. Steroids 1995, 60:210-213.
12. Birzniece V., Turkmen S., Lindblad C., Zhu D., Johansson I.M., Bäckström T., Wahlström G. GABA(A) receptor changes in acute allopregnanolone tolerance. Eur. J. Pharmacol. 2006, 535:125-134.
13. Bixo M., Andersson A., Winblad B., Bäckström T. Progesterone, 5α-pregnane-3,20-dione and 3αhydroxy-5α-pregnane-20-one in specific regions of the human female brain at different endocrine states. Brain Res. 1997, 764:173-178.
14. Björn I., Bixo M., Nöjd K.S., Nyberg S., Bäckström T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am. J. Obstet. Gynecol. 2000, 183:1419-1426.
15. Björn I., Bixo M., Nöjd K.S., Collberg P., Nyberg S., Sundström-Poromaa I., Bäckström T. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol. Endocrinol. 2002, 16:1-8.
16. Brown N., Kerby J., Bonnert T.P., Whiting P.J., Wafford K.A. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br. J. Pharmacol. 2002, 136:965-974.
17. Bäckström T., Sanders D., Leask R., Davidson D., Warner P., Bancroft J. Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychsom. Med. 1983, 45:503-507.
18. Bäckström T., Andreen L., Birzniece V., Björn I., Johansson I.M., Nordenstam-Haghjo M., Nyberg S., Sundström-Poromaa I., Wahlström G., Wang M., Zhu D. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003, 17:325-342.
19. Bäckström T., Bixo M., Nyberg S., Savic I. Increased neurosteroid sensitivity - an explanation to symptoms associated with chronic work related stress in women. Psychoneuroendocrinology 2013, 38(7):1078-1089.
20. Carl P., Högskilde S., Nielsen J.W., Sörensen M.B., Lindholm M., Karlen B., Bäckström T. Pregnaneolone emulsion: a preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaestetic agent. Anaesthesia 1990, 45:189-197.
21. Chan A.F., Mortola J.F., Wood S.H., Yen S.S. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet. Gynecol. 1994, 84:1001-1005.
22. Cherek D.R., Spiga R., Egli M. Effects of response requirement and alcohol on human aggressive responding. J. Exp. Anal. Behav. 1992, 58:577-587.
23. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with placebo. Acta Psychiat. Scand. 1972, 236(Suppl.):1-84.
24. Dennerstein L., Lehert P., Bäckström T.C., Heinemann K. The effect of premenstrual symptoms on activities of daily life. Fertil. Steril. 2010, 94:1059-1064.
25. Dougherty D.M., Cherek D.R., Bennett R.H. The effects of alcohol on the aggressive responding of women. J. Stud. Alcohol 1996, 57:178-186.
26. Epperson C.N., Haga K., Mason G.F., Sellers E., Gueorguieva R., Zhang W., Weiss E., Rothman D.L., Krystal J.H. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 2002, 59:851-858.
27. Epperson C.N., Steiner M., Hartlage S.A., Eriksoon E., Schmidt P., Jones I., Yonkers K.A. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am. J. Psychol. 2012, 169:465-475.
28. Gallo M.A., Smith S.S. Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety. Pharmacol. Biochem. Behav. 1993, 46:897-904.
29. Gangisetty O., Reddy D.S. Neurosteroid withdrawal regulates GABA-A receptor α4 subunit expression and seizure susceptibility by activiation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience 2010, 170:865-880.
30. Genazzani A.R., Petraglia F., Bernardi F., Casarosa E., Salvestroni C., Tonetti A., Nappi R.E., Luisi S., Palumbo M., Purdy R.H., Luisi M. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J. Clin. Endocrinol. Metab. 1998, 83:2099-2103.
31. Gourley S.L., Debold J.F., Yin W., Cook J., Miczek K.A. Benzodiazepines and hightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists. Psychopharmacology (Berl) 2005, 178:232-240.
32. Gulinello M., Gong Q.H., Li X., Smith S.S. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res. 2001, 910:55-66.
33. Halbreich U., Borenstein J., Pearlstein T., Kahn L.S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003, 28(Suppl. 3):1-23.
34. Hall R.C., Zisook S. Paradoxical reactions to benzodiazepines. Br. J. Clin. Pharmacol. 1981, 11(Suppl. 1):99SL 104S.
35. Hammarbäck S., Bäckström T., Holst J., von Schoultz B., Lyrenäs S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement treatment. Acta Obstet. Gynecol. Scand. 1985, 64:393-397.
36. Hammarbäck S., Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet. Gynecol. Scand. 1988, 67:159-166.
37. Hammarbäck S., Ekholm U.B., Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. 1991, 125:132-137.
38. Hartlage S.A., Freels A., Gotman N., Yonkers K.A. Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch. Gen. Psychiatry 2012, 69:300-305.
39. Honan V.J. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest. Endosc. 1994, 40:86-88.
40. Innala E., Bäckström T., Poromaa I.S., Andersson C., Bixo M. Women with acute intermittent porphyria have a defect in 5α-steroid production during the menstrual cycle. Acta Obstet. Gynecol. Scand. 2012, 91:1445-1452.
41. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 1994, 51:8-19.
42. Klotz U., Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin. Pharmacokinet. 1988, 14:1-12.
43. Kurthen M., Linke D.B., Reuter B.M., Hufnagel A., Elger C.E. Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetriesα. Cortex 1991, 27:333-337.
44. Landgren S., Wang M.D., Bäckström T., Johansson S. Interaction between 3 alpha-hydroxy-5 alpha-pregnan-20 one and carbachol in the control of neuroal excitability in hippocampal slices of female rats in defined phases of the oestrus. Acta Physiol. Scand. 1998, 162:77-88.
45. Lee G.P., Loring D.W., Meador K.J., Flanigin H.F., Brooks B.S. Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion. Neurology 1988, 38:1233-1236.
46. Le Mellédo J.M., Van Driel M., Coupland N.J., Lott P., Jhangri G.S. Response to flumazenil in women with premenstrual dysphoric disorder. Am. J. Psych. 2000, 157:821-823.
47. Litchfield B.N. Complications of intravenous diazepam adverse psychological reactions (an assessment of 16,000 cases). Anesth. Prog. 1980, 28:175-183.
48. Luisi S., Petraglia F., Benedetto C., Nappi R.E., Bernardi F., Fadalti M., Reis F.M., Luisi M., Genazzani A.R. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J. Clin. Endocrinol. Metab. 2000, 85:2429-2433.
49. Magos A.L., Brewster E., Sing R., O'Dowd T., Brincat M., Studd J.W. The effect of norethisterone in postmenopausal women on oestrogen therapy: a model for the premenstrual syndrome. Br. J. Obstet. Gynaecol. 1986, 93:1290-1296.
50. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232:1004-1007.
51. Marshall R.W., Griffiths A.N., Richens A. A microcomputer system to assess CNS depression from an analysis of the dynamics of saccadic eye-movements. Br. J. Clin. Pharmacol. 1985, 20:304-305.
52. Masia S.L., Perrine K., Westbrook L., Alper K., Devinsky O. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology 2000, 54:1691-1693.
53. Miczek K.A., Fish E.W., De Bold J.F. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm. Behav. 2003, 44:242-257.
54. Mortola J.F., Girton L., Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J. Clin. Endocrinol. Metab. 1991, 72. 252A-252F.
55. Nyberg S., Wahlström G., Bäckström T., Sundström-Poromaa I. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology 2004, 29:767-777.
56. Nyberg S., Bäckström T., Zingmark E., Purdy R., Sundström-Poromaa I. Allopregnanolone decrease with symptom improvement during placebo and GnRH agonist treatment in women with premenstrual dysphoric disorder. Gynecol. Endocrinol. 2007, 23:257-266.
57. Ossewaarde L., Hermans E.J., vanWingen G.A., Kooijman S.C., Johansson I.M., Bäckström T., Fernández G. Neural mechanisms underlying changes in stress-sensitivity across the menstrual cycle. Psychoneuroendocrinology 2010, 35:47-55.
58. Ossewaarde L., van Wingen G.A., Kooijman S.C., Bäckström T., Fernández G., Hermans E.J. Changes in functioning of mesolimbic incentive processing circuits during the premenstrual phase. Soc. Cogn. Affect Neurosci. 2011, 6:612-620.
59. Ossewaarde L., van Wingen G.A., Rijpkema M., Bäckström T., Hermans E.J., Fernández G. Menstrual cycle-related changes in amygdala morphology is associated with changes in stress sensitivity. Hum. Brain Mapp. 2011, PMID: 22162177. 10.1002/hbm.21502.
60. Ottander U., Sundström Poromaa I., Bjurulf E., Skytt Å., Bäckström T., Olofsson J.I. Allopregnanolone and pregnanolone are produced by the human corpus luteum. Mol. Cell. Endocrinol. 2005, 239:37-44.
61. Paul S.M., Purdy R.H. Neuroactive steriods. FASEB J. 1992, 6:2311-2322.
62. Paulus M.P., Feinstein J.S., Castillo G., Simmons A.N., Stein M.B. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch. Gen. Psychiatry 2005, 62:282-288.
63. Protopopescu T.O., Pan H., Epstein J., Root J., Chang L., Altemus M., Polanecsky M., McEwen B., Stern E., Silbersweig D. Toward a functional neuroanatomy of premenstrual dysphoric disorder. J. Affect Disord. 2008, 108:87-94.
64. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. 1998, 338:209-216.
65. Segebladh B., Borgström A., Nyberg S., Bixo M., Sundström-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 2009, 201(13):e131-e138.
66. Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol. Rev. 1995, 47:181-234.
67. Sieghart W., Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2002, 2:795-816.
68. Smith S.S., Gong Q.H., Hsu F.C., Markowitz R.S., ffrench-Mullen J.M., Li X. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998, 392:926-930.
69. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur. J. Endocrinol. 2001, 145:669-679.
70. Sundström I., Ashbrook D., Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997, 22:25-38.
71. Sundström I., Nyberg S., Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997, 17:370-381.
72. Sundström I., Andersson A., Nyberg S., Ashbrook D., Purdy R.H., Bäckström T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998, 67:126-138.
73. Sur C., Farrar S.J., Kerby J., Whiting P.J., Atack J.R., McKernan M.R. Preferential coassembly of alpha4 and delta subunits of the gamma-aminobutyric acidA receptor in rat thalamus. Mol. Pharmacol. 1999, 56:110-115.
74. Sveinsdóttir H., Bäckström T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet. Gynecol. Scand. 2000, 79:405-413.
75. Timby E., Balgård M., Nyberg S., Spigset O., Andersson A., Porankiewicz-Asplund J., Purdy R.H., Zhu D., Bäckström T., Sundström-Poromaa I. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl) 2006, 186:414-424.
76. Timby E. Allopregnanolone Effects in Women: Clinical Studies in Relation to the Menstrual Cycle, Premenstrual Dysphoric Disorder and Oral Contraceptive Use. 38th Nordic Congress of Obstetrics and Gynecology 17-19 June, Bergen, Norway. PS21.4: 91-92 2012, http://www.mednet.no/nfog2012/abstractbook/index.html.
77. van Wingen G., van Broekhoven F., Verkes R.J., Petersson K.M., Bäckström T., Buitelaar J., Fernándes G. How progesterone impairs memory for biologically salient stimuli in healthy young women. J. Neurosci. 2007, 27:11416-11423.
78. van Wingen G.A., van Broekhoven F., Verkes R.J., Petersson K.M., Bäckström T., Buitelaar J.K., Fernandez G. Progesterone selectively increases amygdala reactivity in women. Mol. Psychiatry 2008, 13:325-333.
79. van Wingen G.A., Ossewaarde L., Bäckström T., Hermans E.J., Fernández G. Gonadal hormone regulation of the emotion circuitry in humans. Neuroscience 2011, 191:38-45.
80. Wang M., Seippel L., Purdy R.H., Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 1996, 81:1076-1082.
81. Wang M., Bäckström T., Sundström I., Wahlström G., Olsson T., Zhu D., Johansson I.M., Björn I., Bixo M. Neuroactive steroids and central nervous system disorders. Int. Rev. Neurobiol. 2001, 46:421-459.
82. Weinbroum A.A., Szold O., Ogorek D., Flaishon R. The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature. Eur. J. Anaesthesiol. 2001, 18:789-797.
83. Weerts E.M., Tornatzky W., Miczek K.A. Anxiolytic and anxiogenic benzodiazepines and beta-carbolines: effects on aggressive and social behavior in rats and squirrel monkeys. Psychopharmacology (Berl) 1993, 110:451-459.
84. Wenzel R.R., Bartel T., Eggebrecht H., Philipp T., Erbel R. Central-nervous side effects of midazolam during transesophageal echocardiography. J. Am. Soc. Echocardiogr. 2002, 15(10 Pt 2):1297-1300.
85. Whittemore E.R., Yang W., Drewe J.A., Woodward R.M. Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes. Mol. Pharmacol. 1996, 50:1364-1375.
86. Wieland S., Lan N.C., Mirasedeghi S., Gee K.W. Anxiolytic activity of the progesterone metabolite 5β-pregnan-3α-ol-20-one. Brain Res. 1991, 565:263-268.
87. Wittchen H.U., Essau C.A., von Zerssen D., Krieg J.C., Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 1992, 241:247-258.
88. Wohlfarth K.M., Bianchi M.T., Macdonald R.L. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J. Neurosci. 2002, 22:1541-1549.